CYRX · CryoPort, Inc.

The thesis

Cryoport's cold-chain business for cell and gene therapies reached positive adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) in the second quarter, and the third-quarter report decides whether that turn lasts. The report is expected around 4 November 2026 (est.). It needs adjusted EBITDA above zero again and commercial therapy revenue growing faster than the 9% reported for the second quarter.

The shares closed at $16.90 on 8 October 2026 in adjusted daily closes. That is 6.8% below the $18.14 close of 5 October 2026, the 52-week high, and down from $17.80 on 6 October 2026. The 14-day relative strength index (RSI) fell to 48.0 on 8 October 2026 from 74.2 on 6 October 2026, so the overbought reading of early October has cleared. No company news explains the two-day drop. Cryoport's investor relations page lists no press release after the 6 August 2026 second-quarter results as of 9 October 2026.

The narrative is maturing: brokers have restated and raised targets since mid-September, but the company has published nothing new since 6 August 2026, and the shares gave back part of the early-October gain within three sessions. One positive quarter is a single data point. The November report has to show a second before the turn counts as a trend.

Bullish and bearish views on CryoPort, Inc.

The bull case on CryoPort, Inc. (CYRX), in brief: Services growth carries the company. The bear case: Commercial therapy growth is modest.

Bull case

• Services growth carries the company. Life Sciences Services revenue rose 15% year over year to $28.0 million in the second quarter and 16% to $54.9 million in the first half (Form 8-K, Exhibit 99.1, 6 August 2026). BioStorage/BioServices revenue grew 25% to $5.6 million, the fastest line in the release.
• Adjusted profitability has turned positive. Adjusted EBITDA was positive $375 thousand in the second quarter, against a $914 thousand loss a year earlier.
• Revenue is tracking the guidance range. First-half 2026 revenue was $96.8 million, up 12%. Management reaffirmed the $192–196 million full-year range on 6 August 2026, according to the release and Seeking Alpha's call coverage.
• The approval pipeline feeds future volume. Cryoport supported 779 clinical trials at 30 June 2026, 94 of them in Phase 3. For the rest of 2026 the company expects up to 11 more biologics or marketing applications and up to five more therapy approvals, according to the 6 August 2026 release.
• Pullback leaves room to analyst targets. The $16.90 close on 8 October 2026 sits below the $18.38 consensus target MarketBeat reported on 2 October 2026, Guggenheim's $19 target set on 1 October 2026 and BTIG's $25 target reiterated on 18 September 2026, according to Benzinga.

Bear case

• Commercial therapy growth is modest. Revenue tied to commercial cell and gene therapies (CGT) grew 9% year over year to $9.4 million in the second quarter, according to the 6 August 2026 release. That line should rise with new approvals, and it has not yet picked up speed.
• Products are flat and margins slipped. Life Sciences Products revenue was $21.0 million in the second quarter, against $21.1 million a year earlier. Products gross margin fell to 42.2% from 44.9%.
• Reported earnings remain negative. Cryoport lost $0.20 per share under generally accepted accounting principles (GAAP) in the second quarter, according to the 6 August 2026 release.
• Officers sold into the rise. The chief financial officer sold 169,427 shares at a weighted $16.27 on 4 June 2026, and the chief executive sold 28,800 shares at $14.91 on 11 August 2026, according to SEC Form 4 filings.
• The rally rested on broker notes. The move to the $18.14 high on 5 October 2026 came with no company release since 6 August 2026, and the shares lost that ground within three sessions without news.

Price setup

The $16.90 close on 8 October 2026 is 7.6% above the close three months earlier and 6.8% below the $18.14 52-week high of 5 October 2026. MarketBeat put the 50-day moving average at $16.01 and the 200-day moving average at $13.95 on 2 October 2026, so the shares still trade above both rising averages.

The $15.12 close on 7 August 2026, the first session after the second-quarter report, marks the start of the post-results re-rating. A weekly close below that level would erase it. Between $16.90 and $15.12, the 50-day average near $16 is the first reference level.

Crowding is moderate. The RSI has cooled to 48.0 from 74.2 in two sessions, officer sales are on record from June and August, and the earnings report falls about four weeks out.

Catalysts, next 30 days

• ~21 October 2026 (est.) — Announcement of the third-quarter results date. The second-quarter date was announced on 23 July 2026, two weeks ahead. No third-quarter date appeared on the investor relations page as of 9 October 2026.
• ~3 November to 4 November 2026 (est.) — Third-quarter 2026 results. Some data feeds list 3 November 2026 after the close; the third-quarter 2025 report came on 4 November 2025. The report tests whether adjusted EBITDA stays positive, whether commercial CGT growth beats 9% and whether the $192–196 million 2026 revenue guidance holds.

What would change the view

The case breaks if the third-quarter report shows adjusted EBITDA back below zero, or if management cuts the $192–196 million 2026 revenue guidance. Commercial CGT growth at or below 9% for a second quarter would weaken it, because new therapy approvals should be lifting that line. A supported-trial count below 779 at 30 September 2026 would point to slowing future volume.

On price, a weekly close below $15.12, the 7 August 2026 close after the second-quarter report, would erase the post-results re-rating. New officer sales on Form 4 ahead of the report would add to the bear case.

What it trades with

Cryoport's customers are cell and gene therapy developers, so biotech funding conditions drive both trial volume and the valuation multiple. The shares tend to trade with small- and mid-cap biotech sentiment more than with the broad market. Company-specific movement is concentrated around quarterly reports, when the commercial therapy revenue line and adjusted EBITDA are disclosed.